Related Experiment Video

Updated: Aug 23, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Antisense targeting protein kinase C alpha and beta1 inhibits gastric carcinogenesis

Xiao-Hua Jiang1, Shui-Ping Tu, Jian-Tao Cui

  • 1Department of Gastroenterology, Rui-jin Hospital, Shanghai, P.R. China.

Cancer Research
|August 18, 2004
PubMed

Insights

Targeting Protein Kinase C alpha (PKCalpha) and PKCbeta1 using antisense therapy significantly inhibited gastric cancer cell growth and tumorigenicity. This approach shows promise for developing new gastric cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • Protein kinase C (PKC) family enzymes are crucial serine/threonine kinases involved in cell signaling pathways regulating proliferation, differentiation, and apoptosis.
  • PKC's role in neoplastic transformation and tumor invasion makes it a potential therapeutic target for anticancer strategies.

Purpose of the Study:

  • To investigate the impact of targeting individual PKC isoforms on gastric carcinogenesis.
  • To evaluate the therapeutic potential of antisense inhibition of specific PKC isoforms in gastric cancer.

Main Methods:

  • Generation of gastric cancer cell lines stably expressing antisense complementary DNA (cDNA) for PKCalpha, PKCbeta1, and PKCbeta2.
  • Characterization of transfectants through assessment of cell morphology, growth, apoptosis, and tumorigenicity in vitro and in vivo.
  • Analysis of transcriptional and DNA binding activity of activator protein following PKC inhibition.

Main Results:

  • Antisense inhibition of PKCalpha and PKCbeta1 resulted in altered cell morphology, significantly reduced cell growth, and enhanced apoptosis.
  • PKCbeta2 inhibition showed no significant effects on cell morphology, growth, or apoptosis.
  • Antisense targeting of PKCalpha and PKCbeta1 suppressed colony formation and xenograft tumor growth in vivo.
  • PKCalpha and PKCbeta1 inhibition decreased activator protein transcriptional and DNA binding activity.

Conclusions:

  • Targeting PKCalpha and PKCbeta1 via antisense technology effectively suppresses gastric cancer progression.
  • PKCalpha and PKCbeta1 may mediate their effects on cell growth through the regulation of activator protein activity.
  • Antisense inhibition of PKCalpha and PKCbeta1 represents a promising therapeutic strategy for gastric cancer.

More Related Videos

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Related Concept Videos

Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...